🏛️ Verified NIH Record • Updated 2026-07-09
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors (NCT05787587)
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: IDEAYA Biosciences
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Who can join: Review the eligibility criteria below.
Location: HonorHealth Research Institute — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (27 Sites)
Showing the first 25 of 27 sites.
- HonorHealth Research Institute — Phoenix, Arizona
- The Angeles Clinic — Los Angeles, California
- Hoag Memorial Hospital — Newport Beach, California
- California Pacific Medical Center — San Francisco, California
- Sarah Cannon Research Institute — Denver, Colorado
- Yale University — New Haven, Connecticut
- Orlando Health — Orlando, Florida
- Emory University — Atlanta, Georgia
- OSF St Francis Medical Center — Peoria, Illinois
- Indiana University — Indianapolis, Indiana
- Dana Faber Cancer Institute — Boston, Massachusetts
- Karmanos Cancer Institute — Detroit, Michigan
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
- Roswell Park Comprehensive Cancer Center — Buffalo, New York
- Columbia University Medical Center — New York, New York
- Weil Cornell University — New York, New York
- Sarah Cannon Research Institute - Oklahoma University — Oklahoma City, Oklahoma
- University of Pennsylvania — Philadelphia, Pennsylvania
- Sarah Cannon Research Institute - Thomas Jefferson University — Philadelphia, Pennsylvania
- Sarah Cannon Research Institute — Nashville, Tennessee
- MD Anderson — Houston, Texas
- NEXT Oncology — Irving, Texas
- NEXT Oncology — San Antonio, Texas
- START Mountain Region — West Valley City, Utah
- NEXT Oncology — Fairfax, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced or Metastatic Solid Tumors
- A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) — Sioux Falls, South Dakota
- A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors — Denver, Colorado
- A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations — San Francisco, California
- Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors — Boston, Massachusetts
- A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors — Birmingham, Alabama
- A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors — Los Angeles, California
Explore by condition: All Advanced or Metastatic Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.